DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
SAN DIEGO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders, today announced a series of management changes to optimize its leadership structure. Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary. Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio. These organizational changes will be effective immediately. The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline.
- Seth Cohen has been appointed as Chief Financial Officer and John Dorbin will assume the position of General Counsel Corporate Secretary.
- Mr. Cohen will be succeeding the outgoing interim CFO and President and Chief Operating Officer, David Marguglio.
- The new team is tasked with operating a lean and effective organization committed to increasing the sales of DMK’s existing commercial products and advancing its clinical pipeline.
- “We welcome Seth and John to our executive leadership team at a critical point for our company,” said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals.